Eli Lilly and Company officially confirmed on Wednesday that it would be purchasing Ventyx Biosciences, Inc. in a $1.2 billion deal.
In a statement, Lilly detailed that it will be giving Ventyx $14 per share of common stock in an all-cash transaction, with the agreement to be closed in the first six months of 2026. The deal is subject to Ventyx shareholders' approval, alongside other customary closing conditions.
"The purchase price payable at closing represents a premium of approximately 62% to the 30-day volume-weighted average trading price of Ventyx's common stock ended on January 5, 2026," Lilly detailed, adding that the boards of both businesses greenlighted the merger
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.